Mode
Text Size
Log in / Sign up

Blood miR-7-5p levels decrease more rapidly in Parkinson's disease patients than in healthy controlsBlood Test Tracks Parkinson's Progress

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that blood miR-7-5p levels are associated with time in Parkinson's disease but do not establish causality.

This longitudinal cohort study from the Parkinson's Progression Markers Initiative (PPMI) included 303 de novo people with Parkinson's disease (PwP) and 159 healthy controls (HCs). The study examined blood miR-7-5p levels over time, comparing them between groups and assessing correlations with clinical measures.

The main finding was that miR-7-5p levels decreased more rapidly in PwP compared to HCs (p = 0.02). Additionally, miR-7-5p levels correlated with time in the study (p = 0.02). Secondary outcomes included scores on the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) for motor and total scores, and serum neurofilament light chain (NfL) levels.

Safety and tolerability were not reported, as no adverse events, serious adverse events, discontinuations, or tolerability data were provided. The study did not report effect sizes or absolute numbers for the main results.

Key limitations include the observational design, which cannot establish causality, and the lack of reported effect sizes or absolute numbers. The follow-up duration was not reported, and funding or conflicts of interest were not disclosed.

In practice, these findings suggest a potential association between declining blood miR-7-5p levels and Parkinson's disease progression, but they are preliminary and require replication in larger, controlled studies before any clinical application.

Imagine waking up with a stiff arm that feels like it is made of stone. You take your medicine, but the stiffness returns by noon. For people with Parkinson's disease, this daily struggle is normal. But there is a hidden clock ticking inside the body that doctors cannot see yet.

Parkinson's disease changes how the brain moves. It affects millions of people worldwide. Currently, doctors guess how fast the disease is growing. They look at symptoms like shaking or tremors. But these signs often appear only after the damage is already done.

This delay is frustrating for patients. It means treatment starts too late. Scientists need a better way to measure the disease early. They need a tool that shows changes before the shaking gets worse.

The surprising shift

For years, researchers looked for proteins in the blood to track the disease. They found some, but they were not perfect. Now, a new type of molecule called microRNA is getting attention. Think of microRNA as tiny messengers that carry instructions to cells.

In people with Parkinson's, these messengers seem to disappear faster than in healthy people. This drop happens even before the patient notices big changes in their movement. It is like a smoke alarm going off before the fire starts.

What scientists didn't expect

The study looked at blood samples from 303 people newly diagnosed with Parkinson's. They also checked 159 healthy people for comparison. The team tracked these individuals over several years. They measured the tiny messengers in the blood at each visit.

They also checked standard scores used to rate Parkinson's symptoms. These scores tell doctors how much trouble a person has with walking, balance, and daily tasks. The goal was to see if the blood test matched the symptom scores.

Think of your cells as a busy city. MicroRNA acts like traffic controllers. They tell other molecules when to speed up or slow down. In Parkinson's, a specific controller called miR-7-5p starts failing.

When this controller stops working, the city gets chaotic. Nerve cells get damaged faster. The disease spreads more quickly. By counting how many controllers are left in the blood, doctors can see how much chaos is happening inside.

The results were clear. The levels of miR-7-7-5p dropped much faster in people with Parkinson's than in healthy people. This drop happened over time, year after year.

The study showed a strong link between the drop in these messengers and the worsening of symptoms. When the blood test showed lower levels, the patient's movement scores got worse too. This suggests the test can track the disease's speed.

This doesn't mean this treatment is available yet.

It is important to understand what this finding means for your health. This is a research tool, not a new medicine. It helps doctors understand the disease better. It does not cure Parkinson's or stop it from happening.

If you or a loved one has Parkinson's, this news is hopeful but not a magic fix. It means scientists are getting closer to early detection. Early detection could lead to better treatments in the future.

You should talk to your doctor about your symptoms. Do not wait for a blood test to tell you something is wrong. Your daily observations are still the most important data.

This study is a step forward, but it is not the final step. More research is needed to prove this works in many different people. Scientists must also figure out if this test can be done in regular clinics.

It will take time to turn this discovery into a standard test. Until then, the focus remains on managing symptoms and staying active. The goal is to give patients more time and better care.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundMicroRNA-7-5p (miR-7-5p) may play a neuroprotective role in people with Parkinson’s disease (PwP), as it has been found to regulate α-synuclein (α-syn) and the NLRP3 inflammasome in animal models of Parkinson’s disease (PD).ObjectiveThe study aimed to investigate the use of miR-7-5p as a potential biomarker for disease progression in PwP by correlating it with time, clinical measures, and neurofilament light chain (NfL).MethodsWe performed a longitudinal retrospective analysis of blood miR-7-5p levels in 303 de novo PwP and 159 healthy controls (HCs) from the Parkinson’s Progression Markers Initiative (PPMI) cohort. In PwP, a linear mixed-effects model was used to examine the association between miR-7-5p levels and time in the study. In addition, linear mixed-effects models were used to examine the associations between longitudinal changes in miR-7-5p and scores on the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), both for motor and total scores, as well as serum NfL levels. These models were also used to compare the associations between changes in miR-7-5p, time in the study, and NfL levels in both PwP and HCs.ResultsmiR-7-5p levels decreased more rapidly in PwP compared to HCs (p = 0.02). In PwP, miR-7-5p levels correlated with time in the study (p 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.